2025
SJR Q2
JCR Q3 · 2
35 eşleşen makale
SCIE
Dergi ayrıntısı
Human Psychopharmacology
- Yayıncı
- John Wiley and Sons Ltd
- Ülke
- United Kingdom · Western Europe
- Tür
- journal
- ISSN
-
0885622210991077
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 0,662
- Quartile Q2
- H-Index 89
- Atıf/yayın 1,89
- Doküman (3y) 89
- Atıf (3y) 208
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 2
- 5Y JIF 1,9
- JCI 0,49
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Neurology Q3
- Neurology (clinical) Q2
- Pharmacology (medical) Q2
- Psychiatry and Mental Health Q2
Alanlar
- Medicine
- Neuroscience
WoS kategorileri
- Clinical Neurology | Pharmacology & Pharmacy | Psychiatry | Psychology
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q3 | 0,662 | 2 | 1,9 | 0,49 | Q3 | 89 |
| 2024 | Q3 | Q3 | 0,51 | 1,7 | 1,8 | 0,47 | Q3 | 87 |
| 2023 | Q3 | Q3 | 0,541 | 1,8 | 1,7 | 0,5 | Q3 | 87 |
| 2022 | Q3 | Q3 | 0,449 | 1,7 | 1,9 | 0,45 | Q3 | 87 |
| 2021 | Q3 | Q3 | 0,448 | 2,1 | 2,5 | 0,45 | Q3 | 87 |
| 2020 | Q3 | Q4 | 0,461 | 1,7 | 2,8 | 0,64 | Q3 | 87 |
| 2019 | Q2 | Q3 | 0,714 | 2,1 | 2,1 | 0,69 | Q2 | 87 |
| 2018 | — | Q2 | — | 2,3 | 2,4 | 0,83 | Q2 | — |
| 2017 | Q1 | Q2 | 1,128 | 2,8 | 2,6 | 0,85 | Q2 | 87 |
| 2016 | Q2 | Q2 | 1,018 | 2,2 | 2,2 | — | — | 87 |
| 2015 | Q2 | Q2 | 0,974 | 2,4 | 2,1 | — | — | 87 |
| 2014 | Q2 | Q2 | 0,818 | 2,2 | 2,4 | — | — | 87 |
| 2013 | Q2 | Q3 | 0,902 | 1,9 | 2,5 | — | — | 87 |
| 2012 | Q1 | Q2 | 0,977 | 2,1 | 2,7 | — | — | 87 |
| 2011 | Q1 | Q2 | 0,997 | 2,5 | 2,6 | — | — | 87 |
| 2010 | Q2 | Q2 | 0,946 | 2,6 | 2,5 | — | — | 87 |
| 2009 | — | Q2 | — | 2,5 | 2,6 | — | — | — |
| 2008 | — | Q2 | — | 2,1 | 2,4 | — | — | — |
| 2007 | — | Q2 | — | 2 | 2 | — | — | — |
| 2006 | — | Q2 | — | 2,4 | — | — | — | — |
| 2005 | — | Q2 | — | 1,9 | — | — | — | — |
| 2004 | — | Q3 | — | 1,2 | — | — | — | — |
| 2003 | — | Q2 | — | 1,4 | — | — | — | — |
| 2002 | — | Q3 | — | 1,2 | — | — | — | — |
| 2001 | — | Q3 | — | 1 | — | — | — | — |
| 2000 | — | Q3 | — | 1,1 | — | — | — | — |
| 1999 | — | Q3 | — | 0,6 | — | — | — | — |
| 1998 | — | Q3 | — | 0,6 | — | — | — | — |
| 1997 | — | Q3 | — | 0,9 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | CLINICAL NEUROLOGY | SCIE | Q3 | Q3 | 188/296 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 249/356 |
| 2025 | PSYCHIATRY | SCIE | Q3 | Q3 | 181/293 |
| 2025 | PSYCHOLOGY | SCIE | Q3 | Q3 | 50/93 |
| 2024 | CLINICAL NEUROLOGY | SCIE | Q3 | Q3 | 202/286 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 256/352 |
| 2024 | PSYCHIATRY | SCIE | Q3 | Q3 | 187/288 |
| 2024 | PSYCHOLOGY | SCIE | Q3 | Q4 | 53/93 |
| 2023 | CLINICAL NEUROLOGY | SCIE | Q3 | Q3 | 190/280 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 240/354 |
| 2023 | PSYCHIATRY | SCIE | Q3 | Q3 | 170/279 |
| 2023 | PSYCHOLOGY | SCIE | Q3 | Q3 | 50/92 |
| 2022 | CLINICAL NEUROLOGY | SCIE | Q4 | Q4 | 179/212 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 237/278 |
| 2022 | PSYCHIATRY | SCIE | Q4 | Q3 | 135/155 |
| 2022 | PSYCHOLOGY | SCIE | Q3 | Q4 | 58/81 |
| 2021 | CLINICAL NEUROLOGY | SCIE | Q4 | Q4 | 171/212 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 225/279 |
| 2021 | PSYCHIATRY | SCIE | Q4 | Q3 | 127/155 |
| 2021 | PSYCHOLOGY | SCIE | Q3 | Q4 | 57/80 |
| 2020 | CLINICAL NEUROLOGY | SCIE | Q4 | Q3 | 180/208 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 239/276 |
| 2020 | PSYCHIATRY | SCIE | Q4 | Q3 | 131/156 |
| 2020 | PSYCHOLOGY | SCIE | Q4 | Q3 | 60/77 |
| 2019 | CLINICAL NEUROLOGY | SCIE | Q3 | Q3 | 136/204 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 187/271 |
| 2019 | PSYCHIATRY | SCIE | Q3 | Q2 | 97/155 |
| 2019 | PSYCHOLOGY | SCIE | Q3 | Q3 | 42/78 |
| 2018 | CLINICAL NEUROLOGY | SCIE | Q3 | Q2 | 122/199 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 161/267 |
| 2018 | PSYCHIATRY | SCIE | Q3 | Q2 | 80/146 |
| 2018 | PSYCHOLOGY | SCIE | Q2 | Q2 | 34/77 |
| 2017 | CLINICAL NEUROLOGY | SCIE | Q2 | Q2 | 86/197 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 108/261 |
| 2017 | PSYCHIATRY | SCIE | Q2 | Q2 | 61/142 |
| 2017 | PSYCHOLOGY | SCIE | Q2 | Q2 | 25/78 |
| 2016 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 108/194 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 149/257 |
| 2016 | PSYCHIATRY | SCIE | Q3 | — | 75/142 |
| 2016 | PSYCHOLOGY | SCIE | Q2 | — | 35/77 |
| 2015 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 90/193 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 119/255 |
| 2015 | PSYCHIATRY | SCIE | Q2 | — | 63/142 |
| 2015 | PSYCHOLOGY | SCIE | Q2 | — | 29/76 |
| 2014 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 107/192 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 135/255 |
| 2014 | PSYCHIATRY | SCIE | Q3 | — | 72/140 |
| 2014 | PSYCHOLOGY | SCIE | Q2 | — | 33/76 |
| 2013 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 114/194 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 159/256 |
| 2013 | PSYCHIATRY | SCIE | Q3 | — | 75/136 |
| 2013 | PSYCHOLOGY | SCIE | Q3 | — | 42/74 |
| 2012 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 94/193 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 141/261 |
| 2012 | PSYCHIATRY | SCIE | Q3 | — | 68/135 |
| 2012 | PSYCHOLOGY | SCIE | Q2 | — | 33/75 |
| 2011 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 78/192 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 111/261 |
| 2011 | PSYCHIATRY | SCIE | Q2 | — | 58/130 |
| 2011 | PSYCHOLOGY | SCIE | Q2 | — | 29/75 |
| 2010 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 72/185 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 103/252 |
| 2010 | PSYCHIATRY | SCIE | Q2 | — | 49/128 |
| 2010 | PSYCHOLOGY | SCIE | Q2 | — | 23/73 |
| 2009 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 68/167 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 107/237 |
| 2009 | PSYCHIATRY | SCIE | Q2 | — | 54/117 |
| 2009 | PSYCHOLOGY | SCIE | Q2 | — | 28/71 |
| 2008 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 78/156 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 125/219 |
| 2008 | PSYCHIATRY | SCIE | Q3 | — | 61/101 |
| 2008 | PSYCHOLOGY | SCIE | Q3 | — | 31/61 |
| 2007 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 71/146 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 106/205 |
| 2007 | PSYCHIATRY | SCIE | Q3 | — | 54/94 |
| 2007 | PSYCHOLOGY | SCIE | Q2 | — | 30/61 |
| 2006 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 53/147 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 81/199 |
| 2006 | PSYCHIATRY | SCIE | Q2 | — | 42/94 |
| 2006 | PSYCHOLOGY | SCIE | Q2 | — | 20/60 |
| 2005 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 65/148 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 95/193 |
| 2005 | PSYCHIATRY | SCIE | Q3 | — | 55/94 |
| 2005 | PSYCHOLOGY | SCIE | Q2 | — | 26/60 |
| 2004 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 79/140 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 128/187 |
| 2004 | PSYCHIATRY | SCIE | Q3 | — | 61/90 |
| 2004 | PSYCHOLOGY | SCIE | Q3 | — | 41/60 |
| 2003 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 67/135 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 109/185 |
| 2003 | PSYCHIATRY | SCIE | Q3 | — | 55/87 |
| 2003 | PSYCHOLOGY | SCIE | Q3 | — | 34/60 |
| 2002 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 77/138 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 117/188 |
| 2002 | PSYCHIATRY | SCIE | Q3 | — | 61/88 |
| 2002 | PSYCHOLOGY | SCIE | Q3 | — | 42/61 |
| 2001 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 83/136 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 123/186 |
| 2001 | PSYCHIATRY | SCIE | Q3 | — | 59/81 |
| 2001 | PSYCHOLOGY | SCIE | Q3 | — | 43/58 |
| 2000 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 69/137 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 107/181 |
| 2000 | PSYCHIATRY | SCIE | Q3 | — | 52/82 |
| 2000 | PSYCHOLOGY | SCIE | Q3 | — | 34/56 |
| 1999 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 99/132 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 140/175 |
| 1999 | PSYCHIATRY | SCIE | Q3 | — | 59/80 |
| 1999 | PSYCHOLOGY | SCIE | Q4 | — | 44/54 |
| 1998 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 93/125 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 128/178 |
| 1998 | PSYCHIATRY | SCIE | Q3 | — | 56/77 |
| 1998 | PSYCHOLOGY | SCIE | Q4 | — | 44/53 |
| 1997 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 59/107 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 95/157 |
| 1997 | PSYCHIATRY | SCIE | Q3 | — | 42/67 |
| 1997 | PSYCHOLOGY | SCIE | Q3 | — | 22/34 |